Managing the patient at risk for a second stroke

Journal of Hypertension, Supplement

Volumn 23, Issue 1, 2005, Pages

  Weber, Michael A ^a,b  

^a Downstate Health Sciences University   (United States)

^b NONE   (United States)

Author keywords

Angiotensin II; Cerebrovascular disease; Early morning blood pressure surge; Stroke; Telmisartan

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; TELMISARTAN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; CANDESARTAN HEXETIL; PLACEBO; VALSARTAN;

BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; STROKE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DEMOGRAPHY; DIABETIC NEUROPATHY; DIURETIC THERAPY; DRUG HALF LIFE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HYPERTENSION; HYPOTHESIS; INCIDENCE; ISCHEMIA; META ANALYSIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PREVALENCE; PROTECTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

EID: 18544363733     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000165627.64686.cc     Document Type: Conference Paper

References (52)

1. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, TX: American Heart Association; 2004.
2. Hack W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, et al. European Stroke Initiative Recommendations for Stroke Management - update 2003. Cerebrovasc Dis 2003; 16:311-337.
3. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996; 27:1459-1466.
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
5. Cohn JN. Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
6. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-776.
7. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.
8. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
9. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine; the VALUE randomised trial. Lancet 2004; 363:2022-2031.
10. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363:2049-2051.
11. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
12. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 348:861-869.
13. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
14. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
15. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
16. Di Tullio MR, Zwas DR, Sacco RL, Sciacca RR, Homma S. Left ventricular mass and geometry and the risk of ischemic stroke. Stroke 2003; 34:2380-2384.
17. Selvetella G, Notte A, Maffei A, Calistri V, Scamardella V, Frati G, et al. Left ventricular hypertrophy is associated with asymptomatic cerebral damage in hypertensive patients. Stroke 2003; 34:1766-1770.
18. Penado S, Cano M, Acha O, Hernandez JL, Riancho JA. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med 2003; 114:206-210.
19. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106:331-336.
20. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41:2197-2204.
21. 1 antagonist. Stroke 2002; 33:2297-2303.
22. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21:2175-2182.
23. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia;in rats. Stroke 1999; 30:2391-2398.
24. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12:70-88.
25. Gendron L, Payet MD, Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J Mol Endocrinol 2003; 31:359-372.
26. 1 receptor-blockade on neurological outcome after focal brain ischemia. Hypertension 2000; 36:656.
27. 1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst 2001; 2:103-106.
28. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43:1343-1347.
29. PATS Collaborating Group. Post-stroke Antihypertensive Treatment Study. A preliminary result. Chin Med J (Engl) 1995; 108:710-717.
30. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
31. MOrbidity and mortality after Stroke - Eprosartan compared with nitrendipine in Secondary prevention (MOSES) study, September 2004. www.moses-study.com. [Accessed 6 October 2004].
32. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001; 10(suppl 1):6-11.
33. Maillard MP, Perregaux C, Centeno C, Stangier J, Wienen W, Brunner HR, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002; 302:1089-1095.
34. Diener HC. Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS): rationale and design. Cerebrovasc Dis 2000; 10:147-150.
35. Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148:52-61.
36. Xu J, Culman J, Blume A, Unger T, Gohlke P. Treatment with telmisartan and lithium of stroke-prone spontaneously hypertensive rats: survival study. Naunyn Schmiedebergs Arch Pharmacol 2002; 365:R67.
37. Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28:149-167.
38. 1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001; 298:62-70.
39. Culman J, von Heyer C, Piepenburg B, Rascher W, Unger T. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats. Eur J Pharmacol 1999; 367:255-265.
40. Elliott WJ. Circadian variation in the timing of stroke onset - a meta-analysis. Stroke 1998; 29:992-996.
41. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406.
42. Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker - telmisartan. Blood Press 2001; 10(suppl 1):27-32.
43. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8:111-117.
44. White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Impact on the early morning period. Am J Hypertens 2004; 17:347-353.
45. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3:295-302.
46. Williams B, Gosse P, Lowe L, Harper R, on behalf of the PRISMA I Study Group. Superior blood pressure reduction in the last 6 h of the dosing interval with once-daily telmisartan versus ramipril. Hypertension 2004; 44:576.
47. Lacourcière Y, Neutel J, Koval SE, Norman PE. A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. Hypertension 2004; 44:576.
48. Diener HC, Cunha L, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
49. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
50. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331-337.
51. Zimmermann M, Unger T. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial programme. Expert Opin Pharmacother 2004; 5:1201-1208.
52. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.